Literature DB >> 6651532

Immunization against influenza by the ocular route. Brief report.

G A Tannock, J A Paul, R D Barry.   

Abstract

The immunogenicity of influenza A strain A/Northern Territory/60/68 for mice when delivered by the ocular, nasal and sub-cutaneous routes was determined according to the dose of infectious virus required to induce inhibition of multiplication of a standard intransal challenge dose in 50 per cent of animals per group 3 weeks after vaccination. For mice inoculated by the ocular route, an immunizing dose of 10(2.89) TCID50 per animal was required. For anesthetised mice vaccinated intranasally and unanaesthetised mice vaccinated sub-cutaneously these figures are less than 10(2.0) and greater than 10(6.0) TCID50 per animal, respectively. The lower immunogenicity of virus delivered by the ocular route compared with the intranasal route can be correlated with a lowered capacity of ocularly administered virus to replicate in the murine respiratory tract.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6651532     DOI: 10.1007/BF01310868

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  4 in total

1.  A clinical trial of WRL 105 strain live attenuated influenza vaccine comparing four methods of intranasal vaccination.

Authors:  W G White; D S Freestone; C H Bowker; G M Barnes; E Letley; R D Ferris
Journal:  Dev Biol Stand       Date:  1976

Review 2.  An analysis of effector T cell generation and function in mice exposed to influenza A or Sendai viruses.

Authors:  G L Ada; K N Leung; H Ertl
Journal:  Immunol Rev       Date:  1981       Impact factor: 12.988

3.  A clearance test in mice using non-adapted viruses to determine the immunogenicity of influenza strains.

Authors:  G A Tannock; M C Wark; L E Smith; M M Sutherland
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

4.  Cross-protection and cross-reactive cytotoxic T cells induced by influenza virus vaccines in mice.

Authors:  R G Webster; B A Askonas
Journal:  Eur J Immunol       Date:  1980-05       Impact factor: 5.532

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.